Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
Regulus Therapeutics (Nasdaq: RGLS), a biopharmaceutical company specializing in microRNA-targeted medicines, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's management team is scheduled to present on Tuesday, August 13th at 8:30 a.m. ET.
Investors and interested parties can access a replay of the live presentation through the investor relations section of Regulus Therapeutics' website at https://ir.regulusrx.com/events. The replay will be available under the "Events and Presentations" tab and will remain archived for 90 days following the presentation date.
Regulus Therapeutics (Nasdaq: RGLS), un'azienda biofarmaceutica specializzata in farmaci mirati ai microRNA, ha annunciato la sua partecipazione al 44° Annual Growth Conference di Canaccord Genuity. Il team di gestione dell'azienda è programmato per presentare martedì 13 agosto alle 8:30 a.m. ET.
Gli investitori e le parti interessate possono accedere alla registrazione della presentazione dal vivo tramite la sezione relazioni con gli investitori del sito web di Regulus Therapeutics all'indirizzo https://ir.regulusrx.com/events. La registrazione sarà disponibile sotto la scheda "Eventi e Presentazioni" e rimarrà archiviata per 90 giorni dopo la data della presentazione.
Regulus Therapeutics (Nasdaq: RGLS), una empresa biofarmacéutica especializada en medicamentos dirigidos a microARN, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity. El equipo de gestión de la empresa está programado para presentar el martes 13 de agosto a las 8:30 a.m. ET.
Los inversores y las partes interesadas pueden acceder a una repetición de la presentación en vivo a través de la sección de relaciones con los inversores del sitio web de Regulus Therapeutics en https://ir.regulusrx.com/events. La repetición estará disponible en la pestaña "Eventos y Presentaciones" y permanecerá archivada por 90 días después de la fecha de la presentación.
Regulus Therapeutics (Nasdaq: RGLS)은 microRNA 표적 의약품에 특화된 생명공학 회사로, Canaccord Genuity 제44회 연례 성장 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 경영진은 8월 13일 화요일 오전 8시 30분 ET에 발표할 예정입니다.
투자자와 관심 있는 분들은 Regulus Therapeutics의 웹사이트의 투자자 관계 섹션에서 라이브 발표의 다시보기를 이용할 수 있습니다: https://ir.regulusrx.com/events. 다시보기는 "이벤트 및 발표" 탭에서 확인할 수 있으며, 발표일로부터 90일간 아카이브되어 유지됩니다.
Regulus Therapeutics (Nasdaq: RGLS), une société bio-pharmaceutique spécialisée dans les médicaments ciblant les microARN, a annoncé sa participation à la 44e Conférence Annuelle de Croissance de Canaccord Genuity. L'équipe de direction de l'entreprise doit présenter le mardi 13 août à 8h30 ET.
Les investisseurs et les parties intéressées peuvent accéder à la rediffusion de la présentation en direct via la section des relations avec les investisseurs du site web de Regulus Therapeutics à l'adresse https://ir.regulusrx.com/events. La rediffusion sera disponible sous l'onglet "Événements et Présentations" et restera archivée pendant 90 jours après la date de la présentation.
Regulus Therapeutics (Nasdaq: RGLS), ein biopharmazeutisches Unternehmen, das sich auf microRNA-gerichtete Medikamente spezialisiert hat, hat seine Teilnahme an der 44. jährlichen Wachstums-Konferenz von Canaccord Genuity angekündigt. Das Management-Team des Unternehmens ist für eine Präsentation am Dienstag, den 13. August um 8:30 Uhr ET eingeplant.
Investoren und Interessierte können über den Bereich Investor Relations der Website von Regulus Therapeutics unter https://ir.regulusrx.com/events eine Aufzeichnung der Live-Präsentation abrufen. Die Aufzeichnung wird unter dem Tab "Veranstaltungen und Präsentationen" verfügbar sein und bleibt 90 Tage lang archiviert nach dem Datum der Präsentation.
- None.
- None.
A replay of the live presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the Company's RGLS8429 program and preclinical pipeline, the potential that RGLS8429 may be eligible for an Accelerated Approval pathway, the expected timing for reporting topline data, and the timing and future occurrence of other preclinical and clinical activities. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that the approach we are taking to discover and develop drugs is novel and may never lead to marketable products, that preliminary or topline results are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and may not be indicative of future results, the FDA has not designated RGLS8429 for an Accelerated Approval pathway and such designation may not lead to a faster development, regulatory review or approval process and does not increase the likelihood that RGLS8429 will receive marketing approval, the risk that preclinical and clinical studies may not be successful, risks related to regulatory review and approval, risks related to our reliance on third-party collaborators and other third parties, risks related to intellectual property, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, the risk that additional toxicology data may be negative, and risks related to our ability to successfully secure and deploy capital. These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission, including under the "Risk Factors" heading of Regulus' quarterly report on Form 10-Q for the quarter ended June 30, 2024. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
View original content to download multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-302214800.html
SOURCE Regulus Therapeutics Inc.
FAQ
When is Regulus Therapeutics (RGLS) presenting at the Canaccord Genuity Growth Conference?
How long will the replay of Regulus Therapeutics' (RGLS) presentation be available?
Where can I find the replay of Regulus Therapeutics' (RGLS) presentation at the Canaccord Genuity conference?
What is the focus of Regulus Therapeutics (RGLS) as a biopharmaceutical company?
